TORQUE’S TORVATOR F

Torque’s Torvator F Tablets contain atorvastatin which is a synthetic lipid-altering agent and Fenofibrate which is a peroxisome proliferator receptor alpha (PPARα) activator.

Categories: ,

Product Description

Description: Torque’s Torvator F Tablets contain atorvastatin which is a synthetic lipid-altering agent and Fenofibrate which is a peroxisome proliferator receptor alpha (PPARα) activator.

Pharmaceutical Dosage Form: Tablet

Route of Administration: Oral

Composition: Each film-coated tablet contains:

Atorvastatin Calcium eq. to Atorvastatin                  10 mg

Fenofibrate I.P. (Micronized)                                   160 mg

Mechanism of Action: Atorvastatin is a selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate. Atorvastatin reduces low density lipoprotein (LDL) production and the number of LDL particles. Fenofibrate increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity).

Indications: Torque’s Torvator F is indicated as an adjunct to diet to reduce elevated total C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types II and II b)

Dosage: As directed by the physician.

Storage: Store at a temperature not exceeding 30°C. Protect from light & moisture

Presentation: 10X10 Tablets

Side effects:

Muscle pain

Headache

Joint Pain

Urinary Tract Infection

Constipation

Flatulence

Dyspepsia

Nausea

Diarrhea

Weakness

Contraindications: Torque’s Torvator F is contraindicated in patients with a known allergy to constituents or excipients, during pregnancy and lactation, in patients with severe hepatic failure or renal impairment.

Drug Interactions: Torque’s Torvator F can cause drug interaction with following drugs:

Cyclosporine

Clarithromycin

Azole Antifungals

Protease Inhibitors (Tipranavir Plus Ritonavir, Telaprevir, Lopinavir, Etc)

CYP3A4 Inhibitors(e.g. Erythromycin, Diltiazem, Verapamil and Fluconazole)

Inducers of CYP3A4 (e.g. Efavirenz, Rifampin, St. John’s Wort)

Fibric Acid Derivatives, Erythromycin, Lipid-Modifying Doses of Niacin, Colchicine

Oral Contraceptives & Warfarin